The L-carnitine has demonstrated effects in the treatment of obesity mainly promoting the fat degradation during exercise.

A randomized, double-blind, placebo-controlled clinical trial will be carry out in 24 woman with body mass index ≥ 25 to 29.9 kg/m2. The patients will receive 1.5 g of L-Carnitine deluded in 250 ml of water or placebo before crossfit training, 5 times a week for 8 weeks. Before and after intervention the investigators evaluate: The body composition (body fat, lean body mass), arm muscle circumference, waist circumference, body weight and body mass index.

Inclusion Criteria:

• Volunteers who practice crossfit regularly (who have 3 months prior to the beginning of the study practicing crossfit).
• Volunteers with a body mass index equal to or greater than 25 Kg/m2.
• Volunteers who do not have allergies to L-Carnitine or any of its components.
• Informed consent signed
• Women with a recommendation of nutrition two weeks prior to the start of the study.
• Body weight stable the last 3 months.

Exclusion Criteria:

• Volunteers with pathologies such as diabetes, hypertension, metabolic syndrome and allergies.
• Women with confirmed or suspected pregnancy.
• Women under lactation and/or puerperium.
• Hypersensibilility to L-Carnitine or Sucralose.
• Kown of renal, hepatic or thyroid deseased.
• Current or previous treatment diet (3 months before inclusion to the study).
• Current pharmacological treatment for loose body weight or 3 months before inclusion to the study.